Alpha ThalassemiaSymptoms, Doctors, Treatments, Advances & More
Learn About Alpha Thalassemia
View Main Condition: Thalassemia
Alpha thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen to cells throughout the body.
Alpha thalassemia typically results from deletions involving the HBA1 and HBA2 genes. Less commonly, changes to the DNA sequence in or near these genes cause alpha thalassemia. Such changes are often referred to as nondeletion variants. Both the HBA1 and HBA2 genes provide instructions for making a protein called alpha-globin, which is a component (subunit) of hemoglobin.
Alpha thalassemia is a fairly common blood disorder worldwide. Thousands of infants with Hb Bart syndrome and HbH disease are born each year, particularly in Southeast Asia. Alpha thalassemia also occurs frequently in people from Mediterranean countries, Africa, the Middle East, India, and Central Asia.
The inheritance of alpha thalassemia is complex. Each person inherits two alpha-globin alleles from each parent. If both parents are missing at least one alpha-globin allele, their children are at risk of having Hb Bart syndrome, HbH disease, or alpha thalassemia trait. The precise risk depends on how many alleles are missing and which combination of the HBA1 and HBA2 genes is affected.
Center For Complex Obstetric Medicine
Dr. Teresa N. Sparks is an obstetrician who specializes in maternal-fetal medicine, managing the health concerns of both mother and fetus through all stages of pregnancy. She cares for women with high-risk pregnancies and those who are considering a high-risk pregnancy. She also specializes in clinical genetics, addressing genetic conditions that affect a woman or baby during pregnancy. Sparks' research investigates the causes of nonimmune hydrops fetalis, a complication of pregnancy that occurs when excessive fluid accumulates in the fetus. Her work focuses on identifying the condition's genetic causes, with the goal of developing more targeted approaches to care both before and after birth. Sparks earned her medical degree at UCSF. She completed a residency through the obstetrics and gynecology program of Brigham and Women's Hospital and Massachusetts General Hospital. She then completed a combined fellowship in maternal-fetal medicine and clinical genetics at UCSF. Sparks is a member of the American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, American College of Medical Genetics and Genomics, and American Medical Association. Dr. Sparks is rated as an Elite provider by MediFind in the treatment of Alpha Thalassemia. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Fetal Edema, Hydrops Fetalis, Hemolytic Disease of the Newborn, and Alpha Thalassemia. Dr. Sparks is board certified in American Board Of OB/Gyn/Maternal & Fetal Medicine, Maternal-Fetal Medicine, American Board Of Medical Genetics And Genomics, Clinical Genetics And Genomics, and American Board Of Obstetrics And Gynecology, Obstetrics & Gynecology. Dr. Sparks is currently accepting new patients.
UCSF Benioff Children's Hospital Oakland
Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is rated as an Elite provider by MediFind in the treatment of Alpha Thalassemia. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.
Paloma Ropero practices practicing medicine in Madrid, Spain. Ms. Ropero is rated as an Elite expert by MediFind in the treatment of Alpha Thalassemia. She is also highly rated in 7 other conditions, according to our data. Her clinical expertise encompasses Alpha Thalassemia, Thalassemia, Hemoglobinopathy, Congenital Hemolytic Anemia, and Splenectomy.
Summary: The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (b-thalassemia) could provide information about the possibil...
Summary: Each year world-wide, 2.5 million fetuses die unexpectedly in the last half of pregnancy, 25,000 in the United States, making fetal demise ten-times more common than Sudden Infant Death Syndrome. This study will apply a novel type of non-invasive monitoring, called fetal magnetocardiography (fMCG) used thus far to successfully evaluate fetal arrhythmias, in order to discover potential hidden elect...
Published Date: December 02, 2022
Published By: National Institutes of Health